OR WAIT 15 SECS
Recipharm has announced a long-term manufacturing pact with Roche, which includes the acquisition of Roche’s solid-dose manufacturing facility in Leganés, Spain.
On Sep. 20, 2017, Recipharm announced a long-term manufacturing pact with Roche. The pact will add EUR 35 million (US$42 million) to Recipharm’s annual sales, matching more than 6% of the company’s current sales.
Under the agreement, Recipharm will acquire a manufacturing facility located in Leganés, Spain, from Roche. The facility produces solid dose products, which will be continued under Recipharm. This acquisition is part of Roche’s larger plan started in 2015 to downsize operations while minimizing job reductions. The pact will also extend collaborative opportunity to Recipharm’s nearby facility in Parets, Spain.
“We are continuing to gain momentum in the CDMO market through our various profitable growth initiatives,” said Thomas Eldered, CEO at Recipharm, in a company press release. “I am therefore delighted to announce this long-term agreement with Roche. It has become clear during our interactions with Roche that we are closely aligned in our ways of doing business, and we look forward to developing this relationship further by providing high-quality, reliable supplies from Leganés in future. In addition, we see a highly interesting business development opportunity to add new customers.”
The acquisition of the Leganés facility and the performance of the agreement will be managed by a 100% owned subsidiary of Recipharm. Closing of the transaction and commencement of supply under the agreement is anticipated by the end of 2017.